Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 901–1,000 of 1,004
Chen, L., Wang, G., Zheng, F., Zhao, H., & Li, H. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3148-4 · Cited by 32
Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back
Salari, P., & Abdollahi, M. R. (2012) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3rk5j · Cited by 33
“Black et al analyzed the results of three bisphosphonate trials, the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON), Pivotal Fracture Trial (PFT), the Fracture Intervention Trial (FIT) and the FIT Long-Term Extension (FLEX) trial.”
BackgroundInfluentialCurrent options for the management of postmenopausal osteoporosis
Lecart, M.-P., & Reginster, J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618123 · Cited by 35
Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment
Ferrari, S., Butler, P. W., Kendler, D. L., Miller, P. D., Roux, C., Wang, A. T., Huang, S., Wagman, R. B., & Lewiecki, E. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00271 · Cited by 30
Parthan, A., Kruse, M., Agodoa, I., Silverman, S. L., & ORWOLL, E. S. (2013) · Bone · doi:10.1016/j.bone.2013.11.002 · Cited by 29
“[39] the results were similar.”
Geusens, P., Roux, C., Reid, D. M., Lems, W. F., Adami, S., Adachi, J. D., Sambrook, P. N., Saag, K. G., Lane, N. E., & Hochberg, M. C. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0773 · Cited by 31
“Mechanisms of action of fracture prevention drugs Fractures can be prevented by drugs that have different, and often opposite, effects on bone remodeling”
BackgroundRan, Z., Wang, Y., Li, J., Xu, W., Jia, T., Cao, B., Luo, D., Ding, Y., Wu, J., Wang, L., et al. (2023) · International Journal of Bioprinting · doi:10.18063/ijb.769 · Cited by 30
Nitric Oxide Donors for the Treatment of Osteoporosis
Jamal, S. A., & Hamilton, C. J. (2011) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0087-7 · Cited by 30
Cremers, S., & Farooki, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05770.x · Cited by 32
Local Strategies to Prevent and Treat Osteoporosis
Torstrick, F. B., & Guldberg, R. E. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0191-6 · Cited by 31
A Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.003 · Cited by 33
Hanley, D. A., McClung, M. R., Davison, K. S., Dian, L., Harris, S. T., Miller, P. D., Lewiecki, E. M., & Kendler, D. L. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.002 · Cited by 31
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease
Lee, O.-L., Horvath, N., Lee, C., Joshua, D., Ho, P. J., Szer, J., Quach, H., Spencer, A. G., Harrison, S. J., Mollee, P. N., et al. (2017) · Internal Medicine Journal · doi:10.1111/imj.13502 · Cited by 35
Aminobisphosphonate‐associated orbital and ocular inflammatory disease
Keren, S., Leibovitch, I., Cnaan, R. B., Neudorfer, M., Tempelhof, O. F., Greenman, Y., Shulman, S., Zur, D., & Habot‐Wilner, Z. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14063 · Cited by 33
“The rate of this side effect decreases by more than one-half with every dose, to a rate of 2.8% after the third dose (Black et al. 2007; Michael Lewiecki 2010; Peterson & Bedrossian 2012).”
BackgroundInfluentialKotán, E. V., Bartha-Lieb, T., Parisek, Z., Meskó, A., Vaszilkó, M., & Hankó, B. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025600 · Cited by 29
Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures
Ding, L., Hu, J., Wang, D., Liu, Q., Mo, Y., Tan, X., & Wen, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz023 · Cited by 32
Riancho, J., Peris, P., González-Macías, J., & Pérez-Castrillón, J.-L. (2022) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2022000100003 · Cited by 47
Management of bone loss due to endocrine therapy during cancer treatment
Khan, M. I. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06672-3 · Cited by 32
“Non-vertebral fractures, clinical fractures, and clinical vertebral fracture risk were reduced by 25%, 33%, and 77% respectively during a 3-year period, as compared to placebo in post-menopausal women with osteoporosis (HORIZON Pivotal Fracture Trial) [25].”
BackgroundGobron, B., Couchot, M., Irwin, N., Legrand, É., Bouvard, B., & Mabilleau, G. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4792 · Cited by 30
“Although this is partly true in osteoporosis, and despite the fact that all approved anti-osteoporotic drugs increase bone mineral density, the risk of bone fracture is only reduced by 30%–40% in hip and long bones in treated individuals.((3-6)) This suggests that factors beyond bonemass are primordial for optimum bon…”
BackgroundChen, L., Wu, X., Jin, Q., Chen, G.-Y., & Ma, X. (2023) · European spine journal · doi:10.1007/s00586-023-07917-9 · Cited by 25
Unilateral Anterior Uveitis Complicating Zoledronic Acid Therapy in Prostate Cancer
Banal, F., Briot, K., Ayoub, G., Dougados, M., & Roux, C. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080273 · Cited by 29
Reynolds, K., Viswanathan, H. N., Muntner, P., Harrison, T. N., Cheetham, T. C., Hsu, J. Y., Gold, D. T., Silverman, S. L., Grauer, A., Morisky, D. E., et al. (2014) · Quality of Life Research · doi:10.1007/s11136-014-0662-3 · Cited by 36
“Clinical trials have demonstrated the efficacy of bisphosphonates (BPs), currently the most commonly prescribed therapy for osteoporosis [2, 4].”
BackgroundLong-term risks of bisphosphonate therapy
Watts, N. B. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003308 · Cited by 31
Kaufman, J.-M., Palacios, S., Silverman, S. L., Sutradhar, S., & Chines, A. A. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2341-6 · Cited by 33
“However, subgroup analyses were justified based on the trend observed in the analysis of the entire population and on the fact that results from the current subgroup analysis showed a magnitude of reductions in vertebral and nonvertebral fracture risk with BZA in women at high probabilities of fracture that approached…”
ResultGreiner, S. H., Kadow‐Romacker, A., Schmidmaier, G., & Wildemann, B. (2008) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32245 · Cited by 30
Rietbrock, S., Olson, M. S., & van Staa, T. P. (2008) · QJM · doi:10.1093/qjmed/hcn130 · Cited by 28
“Recently, a large clinical study found that patients treated with zoledronate, a once-yearly bisphosphonate infusion, had a statistically significant lower risk of hip fracture as well as vertebral and non-vertebral fracture compared with patients using placebo.(9) Given the increasing availability of bisphosphonate w…”
BackgroundTsang, S. W. Y., Bow, C., Chu, E. Y.-W., Yeung, S. C., Soong, C., & Kung, A. W. C. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1260-z · Cited by 30
“Treatment of women with asymptomatic vertebral fractures has been shown to reduce future hip and vertebral fractures [35, 36] and reduce disability [37]; since majority of vertebral fractures are clinically silent, we recommend that caseidentification efforts should focus on older women with multiple risk factors to i…”
BackgroundBell, K., Hayen, A. D., Glasziou, P., Irwig, L., Eastell, R., Harrison, S. L., Black, D. M., & Bauer, D. C. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2847 · Cited by 30
“The design of the HORIZON-PFT trial((17)) and of the randomized extension((18)) have been reported in detail previously.”
MethodSelf-citationDenosumab for the prevention of osteoporotic fractures in postmenopausal women
Waugh, N. R., Royle, P., Scotland, G., Henderson, R., Hollick, R. J., & McNamee, P. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1-06 · Cited by 29
Bone Disease in Multiple Myeloma
Eda, H., Santo, L., Roodman, G. D., & Raje, N. S. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_14 · Cited by 33
“Bisphosphonates have a well-established role in the treatment of osteoporosis [82, 83] and metastatic bone involvement from solid tumors [84–86].”
BackgroundSuzuki, A., Sekiguchi, S., Asano, S., & Itoh, M. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fm0070218 · Cited by 38
Advances in strontium-releasing biomaterials for bone repair
Mehta, D., & Gentleman, E. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123718 · Cited by 30
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2012) · PET Clinics · doi:10.1016/j.cpet.2012.04.001 · Cited by 28
Current and future treatments of osteoporosis in men
Kaufman, J., Lapauw, B., & Goemaere, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.002 · Cited by 30
Gossiel, F., Finigan, J., Jacques, R., Reid, D. M., Felsenberg, D., Roux, C., Glueer, C., & Eastell, R. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2014.68 · Cited by 30
“These data have been supported by other studies.(21,22) The usual approach to establish reference intervals is to define exclusion criteria.”
ResultSelf-citationA review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg
Abelson, A. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260899 · Cited by 28
Misof, B. M., Roschger, P., Gabriel, D., Paschalis, E. P., Eriksen, E. F., Recker, R. R., Gasser, J. A., & Klaushofer, K. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1780 · Cited by 30
Self-citationOsteonecrosis of the Jaw in Older Osteoporosis Patients Treated with Intravenous Bisphosphonates
Baillargeon, J., Kuo, Y. F., Lin, Y., Wilkinson, G. S., & Goodwin, J. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q239 · Cited by 28
Osteoporosis Update From the 2010 Santa Fe Bone Symposium
Lewiecki, E. M., Bilezikian, J. P., Khosla, S., Marcus, R., McClung, M. R., Miller, P. D., Watts, N. B., & Maricic, M. J. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2010.12.001 · Cited by 28
Marques, A., Lourenço, Ó. D., Ortsäter, G., Borgström, F., Kanis, J. А., & da Silva, J. A. P. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0132-8 · Cited by 33
Marine Natural Products: New Avenue in Treatment of Osteoporosis
Chaugule, S. R., Indap, M. M., & Chiplunkar, S. V. (2017) · Frontiers in Marine Science · doi:10.3389/fmars.2017.00384 · Cited by 30
“Currently, Zoledronate is used as only treatment for metastasis associated increased bone resorption (Black et al., 2007; Abrahamsen et al., 2009; Reid and Cornish, 2011; Wolfe et al., 2013).”
BackgroundManagement of fracture risk in Parkinson's: A revised algorithm and focused review of treatments
Henderson, E. J., Lyell, V., Bhimjiyani, A. G., Amin, J., Kobylecki, C., & Gregson, C. L. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.03.021 · Cited by 30
“years, represents an attractive and affordable option, [40] with substantial fracture risk reductions achieved by 3 years (40% non-vertebral and 75% vertebral fracture relative risk reduction) [41].”
BackgroundFerrari, S., Lewiecki, E. M., Butler, P. W., Kendler, D. L., Napoli, N., Huang, S., Crittenden, D. B., Pannacciulli, N., Siris, E. S., & Binkley, N. (2020) · Bone · doi:10.1016/j.bone.2020.115287 · Cited by 29
Sun, Y., Ma, H., Yang, F., Tang, X., Yi, P., & Tan, M. (2021) · BioMed Research International · doi:10.1155/2021/6650358 · Cited by 31
Tai, T., Li, C., Huang, C., Chan, W. P., & Wu, C. (2021) · Bone · doi:10.1016/j.bone.2021.116216 · Cited by 31
Lu, J., Hu, D., Ma, C., & Shuai, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.938447 · Cited by 34
“Patients with postmenopausal osteoporosis who received annual intravenous infusions of zoledronic acid had a 70% reduction in the risk of lumbar vertebrae fracture and a 41% reduction in hip fracture over 3 years, with varying degrees of reduction in other fractures (Black et al., 2007).”
BackgroundUse of Bisphosphonates in Orthopedic Surgery
Lozano‐Calderón, S. A., Colman, M. W., Raskin, K. A., Hornicek, F. J., & Gebhardt, M. C. (2014) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2014.03.006 · Cited by 30
Miller, P. D., Recker, R. R., Harris, S. T., Silverman, S. L., Felsenberg, D., Reginster, J.-Y. L., Day, B.-M., Barr, C. E., & Masanauskaite, D. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2518-z · Cited by 30
“The majority of clinical trials examining the vertebral fracture and NVF efficacy of the approved bisphosphonates (alendronate, risedronate, ibandronate, and zoledronic acid) where a placebo arm has been retained have been 3 to 4 years in duration [17, 39–43], and few studies have examined the long-term benefits of bi…”
BackgroundNagase, S., Ohyama, M., Hashimoto, Y., Small, M., Kuwayama, T., & Deacon, S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011399080 · Cited by 28
Lu, P.-Y., Hsieh, C.-F., Tsai, Y., & Huang, W.-F. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.07.012 · Cited by 30
Tan, W., Sun, J., Zhou, L., Li, Y., & Wu, X. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12429 · Cited by 29
Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention
Yang, X., Deng, Z., Wen, T., Luo, W., Xiao, W., Zhao, R.-B., & Li, Y. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453138 · Cited by 31
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 29
Eastell, R., Black, D. M., Lui, L., Chines, A. A., Marín, F., Khosla, S., de Papp, A. E., Cauley, J. A., Mitlak, B., McCulloch, C. E., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4178 · Cited by 30
“HORIZON 2301((23)) (2007) Zoledronic acid (iv) 7736 73.”
Self-citationAn integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens, G. M., Jackson, R. D., & Lewiecki, E. M. (2007) · PubMed · Cited by 40
Mansjur, K. Q., Kuroda, S., Izawa, T., Maeda, Y., Sato, M., Watanabe, K., Horiuchi, S., & Tanaka, E. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1533-y · Cited by 27
The effects of organic nitrates on osteoporosis: A systematic review
Jamal, S. A., Reid, L. S., & Hamilton, C. J. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2262-9 · Cited by 27
“However, nonvertebral fractures (including fractures of the hip, legs, upper arms, and forearms) account for most of the morbidity, mortality, and costs due to fractures [3] and even the most potent antiresorptive drugs reduce the risk of nonvertebral fractures by less than one third [4–9].”
BackgroundJin, Y., Han, X., Wang, Y., & Fan, Z. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00303-1 · Cited by 31
“31,32 Mechanistically, zoledronate plays antiresorptive roles in osteoporosis treatment by inhibiting osteoclast differentiation and inducing osteoclast apoptosis.”
BackgroundDimai, H. P., Muschitz, C., Amrein, K., Bauer, R., Cejka, D., Gasser, R. W., Gruber, R., Haschka, J., Hasenoehrl, T., Kainberger, F. M., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02441-2 · Cited by 32
The use of combination therapy in the treatment of postmenopausal osteoporosis
Compston, J. E. (2011) · Endocrine · doi:10.1007/s12020-011-9554-2 · Cited by 27
Advances and Unmet Needs in the Therapeutics of Bone Fragility
Ramchand, S. K., & Seeman, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00505 · Cited by 28
Clinical evidence of the effect of bisphosphonates on pregnancy and the infant
Machairiotis, N., Ntali, G., Kouroutou, P., & Michala, L. (2019) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2019-0021 · Cited by 28
Ohbayashi, Y., Iwasaki, A., Nakai, F., Mashiba, T., & Miyake, M. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05199-w · Cited by 32
Cui, L., He, T., Jiang, Y., Li, M., Wang, O., Jiajue, R., Chi, Y., Xu, Q., Xing, X., & Xia, W. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05173-6 · Cited by 30
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 40
Ren, T., Huang, J. W., Sun, W., Wang, G., Wu, Y., Jiang, Z., Lv, Y., Wu, G. J., Cao, J., Liu, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1071946 · Cited by 34
“It is well tolerated in the treatment of osteoporosis (Black et al., 2007).”
BackgroundImpact of Bisphosphonates on the Risk of Atrial Fibrillation
Howard, P. A., Barnes, B. J., Vacek, J. L., Chen, W., & Lai, S. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11584720-000000000-00000 · Cited by 27
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass
Hamdy, R. C. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6287 · Cited by 27
“Nephrotoxicity Annual infusions of zoledronate over a three-year period did not result in any significant deterioration of renal function.(25,72) There was nevertheless a transient increase in serum creatinine levels of more than 0.”
BackgroundMethodInfluentialIs There a Place for Bone Turnover Markers in the Assessment of Osteoporosis and its Treatment?
Devogelaer, J., Boutsen, Y., Gruson, D., & Manicourt, D. H. (2011) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2011.07.002 · Cited by 34
Hadji, P., Gamerdinger, D., Spieler, W., Kann, P. H., Loeffler, H., Articus, K., Moericke, R., & Ziller, V. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1583-4 · Cited by 28
“Consistent with our study, the reduction in bone metabolism markers was sustained until month 12 [17].”
BackgroundResultInfluentialDalbeth, N., Aati, O., Gamble, G. D., Horne, A. M., House, M. E., Roger, M., Doyle, A., Chhana, A., McQueen, F. M., & Reid, I. R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205036 · Cited by 30
Self-citationBone Densitometry: Science and Practice
Blake, G. M., & Fogelman, I. (2012) · Springer eBooks · doi:10.1007/978-3-642-02400-9_38 · Cited by 27
Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX-XXI centuries
Dedov, I. I., Mel'nichenko, G. A., Белая, Ж. Е., & Рожинская, Л. Я. (2011) · Problems of Endocrinology · doi:10.14341/probl201157135-45 · Cited by 43
Alendronate affects calcium dynamics in cardiomyocytes in vitro
Kemeny-Suss, N. M., Kasneci, A., Rivas, D., Afilalo, J., Komarova, S. V., Chalifour, L. E., & Duque, G. (2009) · Vascular Pharmacology · doi:10.1016/j.vph.2009.09.002 · Cited by 32
Everts‐Graber, J., Bonél, H., Lehmann, D., Gahl, B., Häuselmann, H., Studer, U., Ziswiler, H., Reichenbach, S., & Lehmann, T. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06863-y · Cited by 32
Wong, P. D., Chen, W., Ewald, D. P., Girgis, C. M., Rawlin, M., Tsingos, J., & Waters, J. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.52637 · Cited by 50
Fisher, J. E., Rosenberg, E., Santora, A. C., & Reszka, A. A. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9711-0 · Cited by 26
Amugongo, S. K., Yao, W., Jia, J., Dai, W., Lay, Y.-A. E., Jiang, L., Harvey, D. J., Zimmermann, E. A., Schaible, E. G., Dave, N. K. N., et al. (2014) · Bone · doi:10.1016/j.bone.2014.04.033 · Cited by 27
“Alendronate, denosumab, and zoledronic acid also reduce incident hip fracture risk [15,16].”
BackgroundMamtani, M., & Kulkarni, H. R. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0875-4 · Cited by 27
Wu, C., Wang, C., Lu, D.-H., Hsu, L.-H., Yang, K., & Lin, F. (2012) · Biomedical Materials · doi:10.1088/1748-6041/7/3/035009 · Cited by 26
Combined Pharmacologic Therapy in Postmenopausal Osteoporosis
Shen, Y., Gray, D. L., & Martinez, D. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.008 · Cited by 27
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
Møller, A. M. J., Delaissé, J., Olesen, J. B., Bechmann, T., Madsen, J. S., & Søe, K. (2020) · JBMR Plus · doi:10.1002/jbm4.10412 · Cited by 36
“5 mg (per year) as an intravenous infusion.((35,36)) Immediately after infusion of 4-mg Zol, a plasma concentration of around 2.”
BackgroundPereira, R. M. R., Perez, M. O., de Paula, A. P., Moreira, C., Castro, C. H. D. M., Zerbini, C. A. F., Domiciano, D. S., de Azevedo, E., de Mendonça, L. M. C., Shinzato, M. M., et al. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00902-z · Cited by 30
Tanner, C. M., Cummings, S. R., Schwarzschild, M. A., Brown, E. G., Dorsey, E. R., Espay, A. J., Galifianakis, N. B., Goldman, S. M., Litvan, I., Luthra, N., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00162-1 · Cited by 26
Self-citationWhich treatment to prevent an imminent fracture?
Iconaru, L., Baleanu, F., Charles, A., Mugisha, A., Benoit, F., Surquin, M., Karmali, R., Body, J.-J., & Bergmann, P. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101105 · Cited by 30
Bone mineral density and risk of cardiovascular disease in men and women: the HUNT study
Bhatta, L., Cepelis, A., Vikjord, S. A., Malmo, V., Laugsand, L. E., Dalen, H., Langhammer, A., Janszky, I., Strand, L. B., & Brumpton, B. M. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00803-y · Cited by 25
Poggi, C. D., Fusaro, M., Mereu, M. C., Brandi, M. L., & Cianferotti, L. (2022) · Nutrients · doi:10.3390/nu14122369 · Cited by 32
“3%, respectively), with no correlation in time to exposure to the drug [28].”
BackgroundMethodInfluentialGrey, A. B., Bolland, M. J., Mihov, B., Wong, S., Horne, A. M., Gamble, G. D., & Reid, I. R. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2009 · Cited by 31
“However, the effects of antiresorptive agents on bone turnover and BMD in osteopenic populations in phase II trials have consistently been replicated in phase III trials conducted in osteoporotic populations.((1,6,19,20)) Finally, the trial was configured to compare the effects of each zoledronate dose with placebo—co…”
BackgroundSelf-citationFracture prevention in postmenopausal women.
Mosekilde, L., Vestergaard, P., & Langdahl, B. L. (2006) · Europe PMC (PubMed Central) · Cited by 27
Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización
Etxebarría-Foronda, Í., Caeiro-Rey, J. R., Larrainzar‐Garijo, R., Vaquero-Cervino, E., Roca-Ruiz, L., Mesa-Ramos, M., Pérez, J. M., Carpintero-Benítez, P., Cebrián, A. F., & Gil-Garay, E. (2015) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2015.05.007 · Cited by 38
Mosali, P., Bernard, L., Wajed, J., Mohamed, Z., Ewang, M., Moore, A., Fogelman, I., & Hampson, G. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9840-0 · Cited by 26
“Treatment with zoledronate has been shown to be effective at reducing vertebral fracture by 70 % and hip fracture by 44 % in the pivotal HORIZON trial [4].”
The impact of dietary calcium intake and vitamin D status on the effects of zoledronate
Bourke, S., Bolland, M. J., Grey, A. B., Horne, A. M., Wattie, D. J., Wong, S. C. Y., Gamble, G. D., & Reid, I. R. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2117-4 · Cited by 25
“However, the changes in BMD in the two trials were very similar to those observed with zoledronate administered to older women with osteoporosis at higher fracture risk [8].”
BackgroundResultSelf-citation2008 Santa Fe Bone Symposium: update on osteoporosis.
Lewiecki, E., Baim, S., Bilezikian, J., Eastell, R., Leboff, M., & Miller, P. D. (2009) · Journal of clinical densitometry · doi:10.1016/j.jocd.2009.02.002 · Cited by 28
Self-citationBae, S., Sun, S., Aghaloo, T. L., Oh, J.-E., McKenna, C. E., Kang, M., SHIN, K.-H., Tetradis, S., Park, N., & Kim, R. H. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1802 · Cited by 31
“Bisphosphonates (BPs) are the most widely used anti-resorptive agents for osteoporosis, a skeletal disorder characterized by compromised bone strength with an increased risk of fracture (1,2).”
Middleton, E. T., Steel, S. A., Aye, M., & Doherty, S. M. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090821 · Cited by 28
“Previous studies with antiresorptives and anabolic agents demonstrate that changes in BSAP and P1NP usually mirror each other.((24,25)) BSAP is produced by osteoblasts and is a measure of osteoblast activity and number.”
ResultErichsen, R., Christiansen, C. F., Frøslev, T., Jacobsen, J. B., & Sørensen, H. T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.338 · Cited by 26
“Unexpectedly, a clinical trial (Black et al, 2007) followed by two observational studies (Heckbert et al, 2008; Abrahamsen et al, 2009) and two metaanalyses (Loke et al, 2009; Bhuriya et al, 2010) found that bisphosphonates may be associated with increased risk of atrial fibrillation (AF).”
BackgroundCombination Anabolic and Antiresorptive Therapy for Osteoporosis
Cusano, N. E., & Bilezikian, J. P. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.005 · Cited by 26
Medical Treatment of Osteoporotic Vertebral Fractures
Langdahl, B. L., & Harsløf, T. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10392105 · Cited by 31
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Palacios, S., Kalouche-Khalil, L., Rizzoli, R., Zapalowski, C., Resch, H., Adachi, J. D., Gallagher, J. C., Feldman, R. G., Kendler, D. L., Wang, A., et al. (2015) · Climacteric · doi:10.3109/13697137.2015.1045484 · Cited by 29
Yang, S., Chen, Q., Wei, H.-K., Zhang, F., Yang, D., Shen, Y., & Ding, W. (2015) · PubMed · Cited by 29
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.